Eli Lilly Acquires Orna Therapeutics to Enhance Drug Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2026
0mins
Source: Fool
- Market Volatility: Pfizer's stock surged from $33 to nearly $60 in 2020 due to rapid COVID-19 vaccine production, but after a significant drop in 2023, it now trades around $28, indicating the volatility in pharmaceutical demand.
- Patent Expiration Risks: Drug companies face challenges from patent expirations, with typical drug patents lasting 20 years; however, due to lengthy development times, effective market exclusivity often shrinks to just 10 to 12 years, necessitating continuous pipeline replenishment.
- Strategic Acquisition: Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics, which focuses on innovative drugs that manipulate genes and cells within patients, further solidifying its leadership in the lucrative GLP-1 drug category.
- Collaborative Development: Prior to the acquisition, Lilly entered a $350 million collaboration with a Chinese biotech firm to develop treatments for immune disorders and cancer, showcasing its strategic vision for global innovation in drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1065.000
Low
950.00
Averages
1192
High
1500
Current: 1065.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Plans to Acquire Three Companies for Nearly $4 Billion
- Acquisition Plans: Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for nearly $4 billion in cash, with respective deals valued at $1.5 billion, $780 million, and $1.55 billion, indicating a strategic focus on expanding its R&D in infectious diseases.
- Strategic Intent: Chief Scientific Officer Daniel M. Skovronsky stated that these acquisitions reflect a strategy to prevent diseases at their source rather than treating their consequences, highlighting Lilly's proactive approach in public health.
- Curevo's Innovation: Curevo has developed a shingles vaccine for adults, engineered with a synthetic adjuvant to enhance immune system tolerability and reduce side effects, showcasing Lilly's technological prowess in vaccine development.
- Addressing Antimicrobial Resistance: LimmaTech targets bacterial pathogens, including drug-resistant sexually transmitted infections, demonstrating Lilly's commitment to tackling public health challenges and enhancing its competitive position in the market.
See More
Warner Bros Discovery Inc Options Show High Volume Activity
- Surge in Options Volume: Warner Bros Discovery Inc (WBD) has seen an options volume of 131,118 contracts today, equating to approximately 13.1 million shares, which represents a significant 84.2% of its average daily trading volume over the past month.
- High Interest in Put Options: Among WBD's options, the $25 strike put option stands out with 46,002 contracts traded today, representing about 4.6 million shares, indicating market expectations for potential price declines.
- Eli Lilly Options Activity: Concurrently, Eli Lilly (LLY) has recorded an options volume of 27,644 contracts today, approximately 2.8 million shares, which constitutes 80.1% of its average daily trading volume over the past month, reflecting sustained investor interest.
- Active Call Options Trading: For LLY, the $1100 strike call option has seen 3,650 contracts traded today, representing around 365,000 shares, suggesting increased market confidence in the stock's future upward movement.
See More
Midday Trading Highlights in US Stocks
- Micron Technology Surge: Micron's shares soared nearly 18%, elevating its market cap to $1 trillion, as UBS raised its price target from $535 to $1,625, indicating a potential doubling of share value, reflecting strong market confidence in the semiconductor sector.
- Semiconductor Sector Rally: The VanEck Semiconductor ETF (SMH) rose over 3%, reaching a new 52-week high, with On Semiconductor and Western Digital both gaining nearly 9%, showcasing investor optimism regarding the recovery of the chip industry.
- Oklo Nuclear Tech Progress: Oklo's stock increased by 6% after being selected by the Department of Energy for discussions on using Cold War-era plutonium as fuel, indicating the company's strategic collaboration potential in the nuclear energy sector.
- Modine Manufacturing Agreement: Modine's shares jumped 16% after announcing a $4 billion agreement with a strategic data center customer, expected to significantly enhance revenue and market position through 2029.
See More
Key Highlights from Tuesday's Investing Club Meeting
- Market Rally: The S&P 500 rose on Tuesday, primarily driven by technology stocks like Micron, Western Digital, and Seagate, reflecting investor optimism about a potential U.S.-Iran deal to end the conflict.
- Arm Stock Trim: Following a 46% gain last week, Jim Cramer decided to trim his position in Arm, emphasizing the importance of taking profits rather than chasing parabolic moves to maintain portfolio stability.
- Eli Lilly Acquisition Plans: Eli Lilly announced plans to acquire three companies for a total of $3.83 billion to expand its infectious disease vaccine business, indicating ongoing investment and strategic shifts in drug development, which led to a stock price increase of over 1%.
- Qnity Stock Potential: Qnity shares rose more than 3%, with Jim suggesting that if coverage expands beyond a limited number of analysts, the stock could reach $250, highlighting the growing demand for materials used in advanced computer chips.
See More
Market Dynamics and Investment Opportunities Analysis
- Optimistic Market Outlook: Stock futures are up significantly due to hopes for a peace deal between the U.S. and Iran, with crude oil prices rebounding from morning lows, indicating market sensitivity to geopolitical risks that could affect energy stocks.
- Tech Stock Focus: Analyst recommendations for Dell highlight its advantages in AI infrastructure integration, potentially driving its stock price higher, while Intel's shares have surpassed $120, with expectations of reaching $150, reflecting strong demand in the semiconductor sector.
- Data Storage Industry Prospects: Evercore ISI raised Western Digital's price target to $575, emphasizing the critical role of data storage in the AI ecosystem, and despite its stock rising over 180%, the market still appears to undervalue this sector.
- Software Industry Challenges: Goldman Sachs lowered Workday's price target to $151 due to concerns about its AI integration, reflecting intensified competition in the enterprise software market that could pressure related software stocks.
See More
Eli Lilly Acquires Three Biotech Firms to Expand Infectious Disease Pipeline
- Acquisition Scale: Eli Lilly announced acquisitions of Curevo for up to $1.5 billion, LimmaTech for $780 million, and Vaccine Company for $1.55 billion, demonstrating its ambition in the infectious disease research sector and broadening its business scope.
- Vaccine Development Progress: Curevo is developing Amezosvatein, a shingles vaccine that in Phase 2 studies significantly reduced fatigue, chills, and injection-site pain while matching immune responses to existing treatments, potentially offering a safer market alternative.
- New Technology Platform: LimmaTech Biologics focuses on vaccines against drug-resistant bacterial infections, with its lead candidate currently in Phase 1 testing, which if successful, could provide new solutions for combating diseases like Gonorrhea and Chlamydia, enhancing Lilly's product line.
- Gene Editing Treatment: On Monday, Eli Lilly released early data for Verve-102, a gene-editing treatment designed to permanently lower bad cholesterol, showcasing its potential in cardiovascular health and further solidifying its leadership in the biopharmaceutical industry.
See More
Eli Lilly Plans to Acquire Three Companies for Nearly $4 Billion
- Acquisition Plans: Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for nearly $4 billion in cash, with respective deals valued at $1.5 billion, $780 million, and $1.55 billion, indicating a strategic focus on expanding its R&D in infectious diseases.
- Strategic Intent: Chief Scientific Officer Daniel M. Skovronsky stated that these acquisitions reflect a strategy to prevent diseases at their source rather than treating their consequences, highlighting Lilly's proactive approach in public health.
- Curevo's Innovation: Curevo has developed a shingles vaccine for adults, engineered with a synthetic adjuvant to enhance immune system tolerability and reduce side effects, showcasing Lilly's technological prowess in vaccine development.
- Addressing Antimicrobial Resistance: LimmaTech targets bacterial pathogens, including drug-resistant sexually transmitted infections, demonstrating Lilly's commitment to tackling public health challenges and enhancing its competitive position in the market.
See More
Warner Bros Discovery Inc Options Show High Volume Activity
- Surge in Options Volume: Warner Bros Discovery Inc (WBD) has seen an options volume of 131,118 contracts today, equating to approximately 13.1 million shares, which represents a significant 84.2% of its average daily trading volume over the past month.
- High Interest in Put Options: Among WBD's options, the $25 strike put option stands out with 46,002 contracts traded today, representing about 4.6 million shares, indicating market expectations for potential price declines.
- Eli Lilly Options Activity: Concurrently, Eli Lilly (LLY) has recorded an options volume of 27,644 contracts today, approximately 2.8 million shares, which constitutes 80.1% of its average daily trading volume over the past month, reflecting sustained investor interest.
- Active Call Options Trading: For LLY, the $1100 strike call option has seen 3,650 contracts traded today, representing around 365,000 shares, suggesting increased market confidence in the stock's future upward movement.
See More
Midday Trading Highlights in US Stocks
- Micron Technology Surge: Micron's shares soared nearly 18%, elevating its market cap to $1 trillion, as UBS raised its price target from $535 to $1,625, indicating a potential doubling of share value, reflecting strong market confidence in the semiconductor sector.
- Semiconductor Sector Rally: The VanEck Semiconductor ETF (SMH) rose over 3%, reaching a new 52-week high, with On Semiconductor and Western Digital both gaining nearly 9%, showcasing investor optimism regarding the recovery of the chip industry.
- Oklo Nuclear Tech Progress: Oklo's stock increased by 6% after being selected by the Department of Energy for discussions on using Cold War-era plutonium as fuel, indicating the company's strategic collaboration potential in the nuclear energy sector.
- Modine Manufacturing Agreement: Modine's shares jumped 16% after announcing a $4 billion agreement with a strategic data center customer, expected to significantly enhance revenue and market position through 2029.
See More
Key Highlights from Tuesday's Investing Club Meeting
- Market Rally: The S&P 500 rose on Tuesday, primarily driven by technology stocks like Micron, Western Digital, and Seagate, reflecting investor optimism about a potential U.S.-Iran deal to end the conflict.
- Arm Stock Trim: Following a 46% gain last week, Jim Cramer decided to trim his position in Arm, emphasizing the importance of taking profits rather than chasing parabolic moves to maintain portfolio stability.
- Eli Lilly Acquisition Plans: Eli Lilly announced plans to acquire three companies for a total of $3.83 billion to expand its infectious disease vaccine business, indicating ongoing investment and strategic shifts in drug development, which led to a stock price increase of over 1%.
- Qnity Stock Potential: Qnity shares rose more than 3%, with Jim suggesting that if coverage expands beyond a limited number of analysts, the stock could reach $250, highlighting the growing demand for materials used in advanced computer chips.
See More
Market Dynamics and Investment Opportunities Analysis
- Optimistic Market Outlook: Stock futures are up significantly due to hopes for a peace deal between the U.S. and Iran, with crude oil prices rebounding from morning lows, indicating market sensitivity to geopolitical risks that could affect energy stocks.
- Tech Stock Focus: Analyst recommendations for Dell highlight its advantages in AI infrastructure integration, potentially driving its stock price higher, while Intel's shares have surpassed $120, with expectations of reaching $150, reflecting strong demand in the semiconductor sector.
- Data Storage Industry Prospects: Evercore ISI raised Western Digital's price target to $575, emphasizing the critical role of data storage in the AI ecosystem, and despite its stock rising over 180%, the market still appears to undervalue this sector.
- Software Industry Challenges: Goldman Sachs lowered Workday's price target to $151 due to concerns about its AI integration, reflecting intensified competition in the enterprise software market that could pressure related software stocks.
See More
Eli Lilly Acquires Three Biotech Firms to Expand Infectious Disease Pipeline
- Acquisition Scale: Eli Lilly announced acquisitions of Curevo for up to $1.5 billion, LimmaTech for $780 million, and Vaccine Company for $1.55 billion, demonstrating its ambition in the infectious disease research sector and broadening its business scope.
- Vaccine Development Progress: Curevo is developing Amezosvatein, a shingles vaccine that in Phase 2 studies significantly reduced fatigue, chills, and injection-site pain while matching immune responses to existing treatments, potentially offering a safer market alternative.
- New Technology Platform: LimmaTech Biologics focuses on vaccines against drug-resistant bacterial infections, with its lead candidate currently in Phase 1 testing, which if successful, could provide new solutions for combating diseases like Gonorrhea and Chlamydia, enhancing Lilly's product line.
- Gene Editing Treatment: On Monday, Eli Lilly released early data for Verve-102, a gene-editing treatment designed to permanently lower bad cholesterol, showcasing its potential in cardiovascular health and further solidifying its leadership in the biopharmaceutical industry.
See More
